Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 5, 2014, Pages 1147-1154

  Toft, Lars ^a   Tolstrup, Martin ^a   Müller, Martin ^b   Sehr, Peter ^c   Bonde, Jesper ^d   Storgaard, Merete ^a   Østergaard, Lars ^a   Søgaard, Ole S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d Mental Health Center Glostrup   (Denmark)

Author keywords

Cervarix; Cross neutralization; Gardasil; HPV vaccines; Neutralizing antibodies; Serology

Indexed keywords

ANTIRETROVIRUS AGENT; NEUTRALIZING ANTIBODY; VIRUS DNA; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEX DIFFERENCE; VIRUS LOAD; VIRUS NEUTRALIZATION; ALPHAPAPILLOMAVIRUS; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HIV INFECTIONS; IMMUNOGENETICS; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; SEROTYPING;

ADULT; ALPHAPAPILLOMAVIRUS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMAN PAPILLOMAVIRUS 31; HUMANS; IMMUNOGENETIC PHENOMENA; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEROTYPING;

EID: 84901411221     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27925     Document Type: Article

References (39)

1. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-65; PMID:11919208; http://dx.doi.org/10.1136/jcp.55.4.244
2. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24 Suppl 3:S3/1-10.
3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370:890-907; PMID:17826171; http://dx.doi.org/10.1016/S0140-6736(07)61416-0
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9; PMID:10451482; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1〈12:: AID-PATH431〉3.0.CO;2-F
5. Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Clin Infect Dis 2007; 45:609-7; PMID:17682997; http://dx.doi.org/10.1086/520654
6. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. [Cervarix]. Drugs 2008; 68:359-72; PMID:18257611; http://dx.doi.org/10.2165/00003495-200868030-00007
7. Monie A, Hung CF, Roden R, Wu TC. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008; 2:97-105; PMID:19707432
8. Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 2006; 66:1263-71, discussion 1272-3; PMID:16827602; http://dx.doi.org/10.2165/00003495-200666090-00008
9. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8
10. Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781-9; PMID:22920953; http://dx.doi.org/10.1016/S1473-3099(12)70187-1
11. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, et al.; HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100-10; PMID:22075170; http://dx.doi.org/10.1016/ S1470-2045(11)70287-X
12. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09) 61248-4
13. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199:936-44; PMID:19236277; http://dx.doi.org/10.1086/597309
14. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-35; PMID:19236279; http://dx.doi.org/10.1086/597307
15. Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother 2013; 9:1399-406; PMID:23571174; http://dx.doi.org/10.4161/hv.24340
16. Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 2004; 328:57-63; PMID:15254442; http://dx.doi.org/10.1097/00000441-200407000-00008
17. Gormley RH, Kovarik CL. Dermatologic manifestations of HPV in HIV-infected individuals. Curr HIV/AIDS Rep 2009; 6:130-8; PMID:19589298; http://dx.doi.org/10.1007/s11904-009-0018-8
18. De Panfilis G, Melzani G, Mori G, Ghidini A, Graifemberghi S. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis 2002; 29:121-5; PMID:11875372; http://dx.doi.org/10.1097/00007435-200203000-00001
19. Sunesen KG, Nørgaard M, Thorlacius-Ussing O, Laurberg S. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. Int J Cancer 2010; 127: 675-84; PMID:19960431; http://dx.doi.org/10.1002/ijc.25080
20. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67; PMID:17617273; http://dx.doi.org/10.1016/ S0140-6736(07)61050-2
21. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-36; PMID:18490686; http://dx.doi.org/10.7326/0003- 4819-148-10-200805200-00005
22. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Mary-Krause M; FHDH-ANRS CO 4. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22:1203-11; PMID:18525266; http://dx.doi.org/10.1097/QAD.0b013e3283023f78
23. Jessica A. Kahn, Jiahong Xu, Bill G. Kapogiannis, Bret Rudy, René Gonin, Nancy Liu, et al. Immunogenicity and Safety of the Human Papillomavirus-6, -11, -16, -18 Vaccine in HIV-Infected Young Women. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2013.
24. rd, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, et al.; IMPAACT P1047 Protocol Team. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55:197-204; PMID:20574412; http://dx.doi.org/10.1097/ QAI.0b013e3181de8d26
25. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, et al.; HPV-010 Study Group. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011; 7:1359-73; PMID:22048172; http://dx.doi.org/10.4161/hv.7.12.18282
26. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246-53; PMID:20812850; http://dx.doi.org/10.1086/656320
27. Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, Durand C, Hervé C, Descamps D. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 2013; 31:5745-53; PMID:24091311; http://dx.doi.org/10.1016/j.vaccine.2013.09.032
28. Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, Ostergaard L, Søgaard OS. Comparison of the Immunogenicity and Reactogenicity of Cervarix and Gardasil Human Papillomavirus Vaccines in HIV-Infected Adults: A Randomized, Double-Blind Clinical Trial. J Infect Dis 2013; PMID:24273179; http://dx.doi.org/10.1093/infdis/jit657
29. rd, Bryan J, Levin MJ; IMPAACT/PACTG P1047 Team. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis 2012; 206:1309-18; PMID:22859825; http://dx.doi.org/10. 1093/infdis/jis489
30. Sehr P, Rubio I, Seitz H, Putzker K, Ribeiro-Müller L, Pawlita M, Müller M. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papilloma-viruses. PLoS One 2013; 8:e75677; PMID:24124504; http://dx.doi.org/10. 1371/journal.pone.0075677
31. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011; 105 :28-37; PMID:21629249; http://dx.doi.org/10.1038/bjc.2011.185
32. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009; 5:696-704; PMID:19855170; http://dx.doi.org/10.4161/hv.5.10.9515
33. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr., Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365 :1576-85; PMID:22029979; http://dx.doi.org/10.1056/NEJMoa1010971
34. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr., Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364 : 401-11; PMID: 21288094; http://dx.doi.org/10.1056/NEJMoa0909537
35. Green MS, Shohat T, Lerman Y, Cohen D, Slepon R, Duvdevani P, Varsano N, Dagan R, Mendelson E. Sex differences in the humoral antibody response to live measles vaccine in young adults. Int J Epidemiol 1994; 23:1078-81; PMID:7860159; http://dx.doi.org/10.1093/ije/23.5.1078
36. Klein SL. Sex differences in prophylaxis and therapeutic treatments for viral diseases. Handb Exp Pharmacol 2012; •••:499-522; PMID:23027464
37. Seitz H, Schmitt M, Böhmer G, Kopp-Schneider A, Müller M. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. Int J Cancer 2013; 132:E139-48; PMID:22961598; http://dx.doi.org/10.1002/ijc.27831
38. Castro F, Dirks WG, Fähnrich S, Hotz-Wagenblatt A, Pawlita M, Schmitt M. High-throughput SNP-based authentication of human cell lines. Int J Cancer 2013; 132:308-14; PMID:22700458; http://dx.doi.org/10.1002/ijc.27675
39. Schmitt M, Pawlita M. High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res 2009; 37:e119; PMID:19589807; http://dx.doi.org/10.1093/nar/gkp581